Pfizer's $43B Seagen bet holds on the assets it bought, not the ones it built

Three years on, the 4 marketed ADCs all deliver and the 9-asset inherited pipeline has 0 new approvals

Seagen-acquired ADC portfolio - status June 2026 (n=13)

Delivering (approved & expanding) · Phase 3 miss · Discontinued · Unproven (Ph1 / planned)

Marketed at acquisition — 4 of 4 delivering

Padcev (enfortumab vedotin)	Nectin-4	DELIVERING
Adcetris (brentuximab vedotin)	CD30	DELIVERING
Tivdak (tisotumab vedotin)	Tissue factor	DELIVERING
Disitamab vedotin (RC48)	HER2 (China-approved)	DELIVERING

Inherited pipeline - the bet — 0 of 9 approved

Sigvotatug vedotin (SGN-B6A)	Integrin beta-6	PHASE 3 MISS
Felmetatug vedotin (SGN-B7H4V)	B7-H4	DISCONTINUED
SGN-CD228A	CD228	DISCONTINUED
SGN-35C	CD30	DISCONTINUED
PDL1V (PF-08046054)	PD-L1 (Ph3 planned)	UNPROVEN
SGN-35T	CD30	DISCONTINUED
MesoC2 (SGN-MesoC2)	MSLN (Ph1)	UNPROVEN
Precemtabart tocentecan	CEACAM5 (Ph1)	UNPROVEN
PF-08046876 (B6C)	Integrin beta-6 (early)	UNPROVEN

Sleuth competitive intelligence, Seagen-origin ADC scorecard. The universe is the 13 antibody-drug conjugates in Seagen's portfolio at the Pfizer acquisition close on 14 December 2023 (n=13), with tucatinib excluded as a TKI and PF-08046037 excluded as an ISAC. Snapshot June 2026. Status reflects program status as of June 2026, and the outcome class of delivering, missed, discontinued, or unproven is a judgment call from public readouts, approvals, and disclosed discontinuations, not a head-to-head comparison. Primary anchors are the Pfizer sigvotatug vedotin Phase 3 topline on 21 June 2026 and the Seagen acquisition of $43B, closed 14 December 2023.